Differential Carbohydrate Expression in Tumorigenic vs Nontumorigenic Prostate Cell-Lines

Pacis, Ronald A.; Pilat, Mary Jo; Yamazaki, K.; Pienta, Kenneth J.

doi:10.3892/ijo.7.6.1349

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study showed the localization of these enzymes in cytoplasmic points, suggesting the Golgi apparatus, confirming that the glycosylation process is highly active and that these two enzymes are important for tumor features [25]. Thus, our research corroborates with studies using lectin histochemistry, specific for α1-3 and α1-4 L-fucose in PA [1, 2, 9, 19, 24] and BPH tissues [2, 17], demonstrating for the first time the immunostaining of enzymes responsible for adding fucose residues in prostatic tissues.…”

Section: Discussionsupporting

confidence: 87%

Comparing the Immunoexpression of FUT3 and FUT6 between Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia

Vasconcelos

Ferreira

Lima

et al. 2013

Acta Histochem. Cytochem.

View full text Add to dashboard Cite

Prostatic Adenocarcinoma (PA) and Benign Prostatic Hyperplasia (BPH) have their etiology not fully understood mainly in glycidic aspects. Glycan changes are associated with cell alterations where glycosylation is carried out by glycosyltransferases, such as fucosyltransferases (FUTs). These enzymes catalyze the insertion of L-fucose residues in a variety of glycan structures often in the final stage of glycosylation. The present study aimed to investigate the expression of FUT3 and FUT6 in PA and BPH as well as to correlate immunostaining of these transferases with PA clinic-histopathologic data. The FUT3 and FUT6 expressions were evaluated by immunohistochemistry in formalin-fixed, paraffin-embedded biopsies of PA (n=40) and BPH (n=40). FUT3 and FUT6 showed a high expression in both prostatic diseases, especially FUT6. FUT6 was more immunoexpressed in PA cases than the FUT3 (p<0.0001) as well as in BPH cases but in a not significant way (p=0.0661). Besides, FUT3 was more expressed in BHP lesion than in PA cases (p<0.0001). Our study presented a new data about FUT3 and FUT6 expression in PA and BPH, revealing high FUT6 expression in both lesions and FUT3 overexpression in BHP in relation to PA, proposing that this enzyme could be a promising biomarker for benign prostate alterations.

show abstract

Section: Discussionsupporting

confidence: 87%

Comparing the Immunoexpression of FUT3 and FUT6 between Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia

Vasconcelos

Ferreira

Lima

et al. 2013

Acta Histochem. Cytochem.

View full text Add to dashboard Cite

show abstract

“…The observed differences in WGA binding may also help to explain conflicting results obtained in previous studies, some of which indicated no significant differences in glycoforms between cell lines differing in metastatic potential, − while others did show differences. − Perhaps differences in carbohydrate expression patterns on metastatic cells are correlated less with general changes in metastatic potential than with tissue-specific homing behavior. As before, further study will be required to investigate this hypothesis.…”

Section: Resultsmentioning

confidence: 84%

Analysis of Cell Surface Carbohydrate Expression Patterns in Normal and Tumorigenic Human Breast Cell Lines Using Lectin Arrays

et al. 2007

View full text Add to dashboard Cite

Cell surface carbohydrates play important roles in a wide variety of biological processes including cell adhesion, fertilization, differentiation, development, and tumor cell metastasis. Lectins are proteins of nonimmune origin which recognize and bind to specific carbohydrate structural epitopes. We have recently described the development and use of lectin arrays as tools for the elucidation of the carbohydrate structures expressed on cell surfaces. In the present work this technology is employed for the characterization of differences in carbohydrate expression patterns on normal and tumorigenic human breast cell lines, as well as on sublines differing in their tendency to "home" to different tissues during metastasis. Significant differences were observed, including changes that correlate with metastatic potential as well as with tissue-specific homing of metastatic cells.

show abstract

“…This antigen is a tumor‐associated molecule involved in prostate carcinogenesis; and its expression in prostate cancer cells increases with the development of tumor malignancy . Pacis et al . also studied the relationship between the expression of carbohydrates on the surface of prostate cancer cells and tumor malignancy, and reported that the potential of human prostate cancer cells to metastasize to bone increases with an increase in the expression of carbohydrates terminating in galactose.…”

Section: Discussionmentioning

confidence: 99%

Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment

et al. 2015

View full text Add to dashboard Cite

Bauhinia purprea agglutinin (BPA) is a well‐known lectin that recognizes galactosyl glycoproteins and glycolipids. In the present study, we firstly found that BPA bound to human prostate cancer specimens but not to normal prostate ones. Therefore, we sought to develop BPA‐PEG‐modified liposomes (BPA‐PEG‐LP) encapsulating anticancer drugs for the treatment of prostate cancer. We examined the tumor targetability of BPA‐PEG‐LP with human prostate cancer DU145 cells, and observed that fluorescently labeled BPA‐PEG‐LP dominantly associated with the cells via the interaction between liposome‐surface BPA and cell‐surface galactosyl molecules. We also observed that BPA‐PEG‐LP accumulated in the prostate cancer tissue after the i.v. injection to DU145 solid cancer‐bearing mice, and strongly bound to the cancer cells. In a therapeutic study, DU145 solid cancer‐bearing mice were i.v. injected thrice with BPA‐PEG‐LP encapsulating doxorubicin (BPA‐PEG‐LPDOX, 2 mg/kg/day as the DOX dosage) or PEG‐modified liposomes encapsulating DOX (PEG‐LPDOX). As a result, BPA‐PEG‐LPDOX significantly suppressed the growth of the DU145 cancer cells, whereas PEG‐LPDOX at the same dosage as DOX showed little anti‐cancer effect. The present study suggested that BPA‐PEG‐LP could be a useful drug carrier for the treatment of human prostate cancers.

show abstract

Differential Carbohydrate Expression in Tumorigenic vs Nontumorigenic Prostate Cell-Lines

Cited by 4 publications

References 0 publications

Comparing the Immunoexpression of FUT3 and FUT6 between Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia

Comparing the Immunoexpression of FUT3 and FUT6 between Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia

Analysis of Cell Surface Carbohydrate Expression Patterns in Normal and Tumorigenic Human Breast Cell Lines Using Lectin Arrays

Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment

Contact Info

Product

Resources

About